Arcturus Therapeutics (ARCT) Tops Q1 EPS by $1.81

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.87, $1.81 better than the analyst estimate of $0.06. Revenue for the quarter came in at $80.3 million versus the consensus estimate of $37.94 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results